As part of the START Program, Neurogene will have opportunities for enhanced communications with the FDA, with the aim to further accelerate the pace of NGN-401's development. Two dose levels of NGN-401 are being evaluated in a Phase 1/2 clinical trial.
Neurogene Says NGN-401 Gene Therapy For Rett Syndrome Has Been Selected To Participate In FDA Support For Clinical Trials Advancing Rare Disease Therapeutics Pilot Program
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.